Phase III study comparing gefitinib with gefitinib combined with carboplatin/pemetrexed for advanced non-small cell lung cancer with EGFR mutation (NEJ009)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Sep 2016
At a glance
- Drugs Gefitinib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 04 Oct 2011 New trial record
- 01 Oct 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.